Skip to main content

Table 1 Frequency of RET biomarkers in vandetanib Phase III NSCLC trial program

From: A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies

Clinical study

RET biomarker, n (%) [95% CI]

RETrearrangement

RETamplification

LowRETgene copy number gain

RET expression

Van

Comp

Van

Comp

Van

Comp

Van

Comp

ZODIAC + ZEAL

1

2**

6

7

14

14

16

24

ZEPHYR

2

1

2

3

19

5

18

10

ZEST

0

1**

4

2

8

14

12

10

Untreated*

–

2

2

2

Non-Asian

5/632 (0.8)

19/632 (3.0)

49/632 (7.7)

52/756 (6.9)

[0.3–1.8]

[1.8–4.6]

[5.7–10.0]

[5.2–8.9]

Asian

2/305 (0.7)

7/305 (2.3)

27/305 (8.8)

40/346 (11.6)

[0.1–2.3]

[0.9–4.6]

[5.9–12.5]

[8.4–15.4]

Overall

7/937 (0.7)

26/937 (2.8)

76/937 (8.1)

92/1102 (8.3)

[0.3–1.5]

[1.8–4.0]

[6.4–10.0]

[6.8–10.1]

  1. Comp, comparator; Van, vandetanib. *One patient randomized to ZODIAC and one randomized to ZEAL did not receive treatment. **One RET rearrangement with an unknown, non-KIF5B fusion partner was identified in the ZEAL comparator and one was identified in the ZEST comparator arm.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us